
$4.3B in potential milestones, two deals, one day. $LLY announced partnerships with Haisco ($2.97B) and Hanmi ($1.185B, for Sonefpeglutide) today, both covering metabolic and autoimmune territory.
last week it was three infectious disease acquisitions totaling over $3.8B in potential. the may 20 8-k had $9B in fresh debt to fund Centessa. that's north of $18B in deal commitments across a few weeks.
shareholders voted to reject governance reform on may 7. the board is moving fast and keeping control while doing it.
wiseek.ai/ticker/lly/new…
English












